Business
Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of 6 studies as poster presentation at the AACR Annual Meeting to be held in Chicago, USA, from April 25-30, 2025.
About this update from Mabwell (shanghai) Bioscience Co., Ltd. Class A
[{"type":"text","content":"SHANGHAI, March 26, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of 6 studies as poster presentation at the AACR Annual Meeting to be held in Chicago, USA, from April 25-30, 2025.","length":290,"tagName":"p"},{"type":"text","content":"The AACR Annual Meeting is one of the largest cancer research conferences in the world. The abstracts have been published on the AACR official website.","length":151,"tagName":"p"},{"type":"text","content":"#01Title: A B7-H3-targeting antibody-drug conjugate, 7MW3711, and PARP inhibitors synergistically potentiate the antitumor activity in B7-H3-positive cancersPublished Abstract Number: 830Location: Poster Section 34Poster Board Number: 18Session Date and Time: Apr. 27, 2025 2:00 PM-5:00 PM (local time)","length":313,"tagName":"p"},{"type":"text","content":"#02Title: Design and synthesis of the novel camptothecin analog MF6 for application into site-specific antibody-drug conjugatePublished Abstract Number: 5733Location: Poster Section 25Poster Board Number: 4Session Date and Time: Apr. 29, 2025 2:00 PM-5:00 PM (local time)","length":282,"tagName":"p"},{"type":"text","content":"#03Title: MW-C01/C02, novel CLDN1-targeting antibody-drug conjugates, demonstrate compelling anti-tumor efficacy and favorable safety profiles in preclinical studiesPublished Abstract Number: 1573Location: Poster Section 15Poster Board Number: 22Session Date and Time: Apr. 28, 2025 9:00 AM-12:00 PM (local time)","length":323,"tagName":"p"},{"type":"text","content":"#04Title: 2MW7061, a novel LILRB4xCD3 bispecific T-cell engager targeting monocytic acute myeloid leukemiaPublished Abstract Number: 2116Location: Poster Section 34Poster Board Number: 2Session Date and Time: Apr. 28, 2025 9:00 AM-12:00 PM (local time)","length":263,"tagName":"p"},{"type":"text","content":"#05Title: An innovative T cell engager platform with optimized CD3 affinity and formats for targeting hematologic and solid tumorsPublished Abstract Number: 2866Location: Poster Section 15Poster Board Number: 5Session Date and Time: Apr. 28, 2025 2:00 PM-5:00 PM (local time)","length":286,"tagName":"p"},{"type":"text","content":"#06Title: 7MW4911, a novel cadherin 17-targeting ADC, demonstrates potent efficacy in preclinic...
More updates from Mabwell (shanghai) Bioscience Co., Ltd. Class A